Search Within

Subhiksha Nandakumar

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (25)
  2. Journal Article (22)
Groups
  1. Sloan Kettering Institute Postdocs (47)
  2. Department of Medicine (42)
  3. Solid Tumor Oncology Division (42)
  4. Genitourinary Oncology Service (36)
  5. GSK Faculty (31)
  6. Human Oncology and Pathogenesis Program (29)

More Groups

People
  1. Philip Kantoff (26)
  2. Nikolaus Schultz (21)
  3. Ying Mazzu (21)
  4. Goutam Chakraborty (20)
  5. Yuki Yoshikawa (16)
  6. David Solit (14)

More People

Years
  1. 2025 (1)
  2. 2024 (7)
  3. 2023 (3)
  4. 2022 (12)
  5. 2021 (5)
  6. 2020 (9)

More Years

Publications
  1. Cancer Research (11)
  2. Journal of Clinical Oncology (8)
  3. Clinical Cancer Research (7)
  4. Molecular Oncology (4)
  5. Neuro-Oncology (4)
  6. Acta Neuropathologica Communications (1)

More Publications

Publishers
  1. American Association for Cancer Research (20)
  2. American Society of Clinical Oncology (8)
  3. FEBS Press (4)
  4. Oxford University Press (4)
  5. Nature Publishing Group (3)
  6. BioMed Central Ltd. (1)

More Publishers

Results (47)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer
    Journal Article

    Mazzu, Y. Z.; Liao, Y. R.; Nandakumar, S.; Jehane, L. E.; Koche, R. P.; Rajanala, S. H.; Li, R.; Zhao, H. Y.; Gerke, T. A.; Chakraborty, G.; more...
    Oncogene (2022)

    Fulltext@MSK | Save
  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
    Journal Article

    Nguyen, B.; Fong, C.; Luthra, A.; Smith, S. A.; DiNatale, R. G.; Nandakumar, S.; Walch, H.; Chatila, W. K.; Madupuri, R.; Kundra, R.; more...
    Cell (2022)

    Fulltext@MSK | Save
  • Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
    Journal Article

    Stopsack, K. H.; Nandakumar, S.; Arora, K.; Nguyen, B.; Vasselman, S. E.; Nweji, B.; McBride, S. M.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Bcl-2 inhibitor enhances anti-androgen therapy induced regression of castration sensitive prostate cancer
    Meeting Abstract

    Hirani, R.; Nandakumar, S.; Kalidindi, T.; Fidele, D.; Rajanala, H.; Mazzu, Y.; Yoshikawa, Y.; Jehane, L.; Lee, G. S. M.; de Stanchina, E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Identification and characterization of the PIK3R1-mutant subtype in PI3K-addicted prostate cancer
    Meeting Abstract

    Chakraborty, G.; Nandakumar, S.; Hirani, R.; Rajanala, S. H.; Nguyen, B.; Ghale, R.; Mazzu, Y. Z.; Jehane, L. E.; Lee, G. S. M.; Mucci, L. A.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Integration of genomic and clinical data from 25,000 patients identifies molecular determinants of metastatic potential and organotropisms
    Meeting Abstract

    Nguyen, B.; Fong, C.; DiNatale, R.; Luthra, A.; Nandakumar, S.; Walch, H.; Chatila, W. K.; Rajanna, A.; Solit, D. B.; Berger, M. F.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer
    Meeting Abstract

    Chakraborty, G.; Hirani, R.; Nandakumar, S.; Kalidindi, T. M.; Fidele, D.; Rajanala, S. H.; Mazzu, Y. Z.; Yoshikawa, Y.; Jehane, L. E.; Lee, G. S. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors
    Journal Article

    Chakraborty, G.; Khan Patail, N.; Hirani, R.; Nandakumar, S.; Mazzu, Y. Z.; Yoshikawa, Y.; Atiq, M.; Jehane, L. E.; Stopsack, K. H.; Lee, G. S. M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Integrative analysis of clinical and genomic information identifies predictive markers of metastatic risk
    Meeting Abstract

    Fong, C. J.; Sanchez-Vega, F.; Ngyuen, B.; Luthra, A.; Nandakumar, S.; Walch, H.; Chatila, W.; Rajanna, A.; Zehir, A.; Berger, M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • CDK12 alterations define a distinct molecular subtype of prostate cancers with unique genomic and clinical characteristics
    Meeting Abstract

    Nguyen, B.; Mota, J. M.; Nandakumar, S.; Stopsack, K. H.; Weg, E.; Rathkopf, D.; Morris, M. J.; Scher, H.; Kantoff, P. W.; Gopalan, A.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save